The effects of tegaserod, a 5-HT4 receptor agonist, on gastric emptying in a murine model of diabetes mellitus

被引:26
|
作者
Crowell, MD
Mathis, C
Schettler, VA
Yunus, T
Lacy, BE
机构
[1] Johns Hopkins Univ, Sch Med, Marvin M Schuster Ctr Digest & Motil Disorders, Baltimore, MD USA
[2] Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, Scottsdale, AZ USA
[3] Mayo Clin Arizona, Scottsdale, AZ USA
关键词
diabetes mellitus; gastroparesis; serotonin type-4 receptor agonist; tegaserod;
D O I
10.1111/j.1365-2982.2005.00681.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The C57BLKS/J db/db transgenic mouse is a model of diabetes mellitus that has been shown to have delayed gastric emptying. We assessed gastric emptying rates in C57BLKS/J mice, and determined the effects of tegaserod, a new selective 5-HT4 receptor partial agonist, on gastric emptying. Methods: Gastric emptying rates of a 20% glucose test meal were determined in 12-20-week-old female db/db mice and control littermates. The effects of tegaserod (0.1-2.0 mg kg(-1), i.p.) on gastric transit were tested in a second group of db/db mice. Pretreatment with GR11308, a specific 5-HT4 antagonist, was used to confirm the mechanism of action of tegaserod on gastric emptying. Results: Gastric emptying of glucose was significantly slower in db/db mice than in control littermates. Tegaserod (0.1 mg kg-1) significantly accelerated the gastric emptying rate of glucose in db/db mice, reducing the fraction of the meal remaining in the stomach at 30 min by 80%. GR11308 blocked the gastrokinetic effects of tegaserod. Conclusions: Gastric emptying was impaired in db/db mice. Low dose tegaserod improved gastric emptying rates in this model of gastroparesis through the activation of 5-HT4 receptors. These findings suggest that 5-HT4 receptor agonists may prove useful for improving delayed gastric emptying in gastroparesis.
引用
收藏
页码:738 / 743
页数:6
相关论文
共 46 条
  • [21] Efficacy and Safety of 5-HT4 Receptor Agonist Minesapride for Irritable Bowel Syndrome with Constipation in a Randomized Controlled Trial
    Fukudo, Shin
    Nakamura, Masatoshi
    Hamatani, Tatsuto
    Kazumori, Kiyoyasu
    Miwa, Hiroto
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (03) : 538 - +
  • [22] The in vivo gastrointestinal activity of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity
    Beattie, D. T.
    Armstrong, S. R.
    Shaw, J. -P.
    Marquess, D.
    Sandlund, C.
    Smith, J. A. M.
    Taylor, J. A.
    Humphrey, P. P. A.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2008, 378 (01) : 139 - 147
  • [23] The in vivo gastrointestinal activity of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity
    D. T. Beattie
    S. R. Armstrong
    J.-P. Shaw
    D. Marquess
    C. Sandlund
    J. A. M. Smith
    J. A. Taylor
    P. P. A. Humphrey
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 378 : 139 - 147
  • [24] Metabolism and Pharmacokinetics of Naronapride (ATI-7505), a Serotonin 5-HT4 Receptor Agonist for Gastrointestinal Motility Disorders
    Bowersox, S. Scott
    Lightning, Luke K.
    Rao, Satish
    Palme, Monica
    Ellis, Dave
    Coleman, Renee
    Davies, Adrian M.
    Kumaraswamy, Padmapriya
    Druzgala, Pascal
    DRUG METABOLISM AND DISPOSITION, 2011, 39 (07) : 1170 - 1180
  • [25] Effect of 5-HT4 receptor agonist mosapride citrate on rectosigmoid sensorimotor function in patients with irritable bowel syndrome
    Kanazawa, M.
    Watanabe, S.
    Tana, C.
    Komuro, H.
    Aoki, M.
    Fukudo, S.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2011, 23 (08) : 754 - E332
  • [26] Randomized clinical trial: a controlled pilot trial of the 5-HT4 receptor agonist revexepride in patients with symptoms suggestive of gastroparesis
    Tack, J.
    Rotondo, A.
    Meulemans, A.
    Thielemans, L.
    Cools, M.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2016, 28 (04) : 487 - 497
  • [27] Activation of islet 5-HT4 receptor regulates glycemic control through promoting insulin secretion
    Chen, Hui
    Hong, Feng
    Chen, Ye
    Li, Ji
    Yao, Yuan-Sheng
    Zhang, Yue
    Zheng, Li-Fei
    Zhu, Jin-Xia
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2016, 789 : 354 - 361
  • [28] An in vitro investigation of the cardiovascular effects of the 5-HT4 receptor selective agonists, velusetrag and TD-8954
    Beattie, D. T.
    Higgins, D. L.
    Ero, M. P.
    Amagasu, S. M.
    Vickery, R. G.
    Kersey, K.
    Hopkins, A.
    Smith, J. A. M.
    VASCULAR PHARMACOLOGY, 2013, 58 (1-2) : 150 - 156
  • [29] The in vitro pharmacology and non-clinical cardiovascular safety studies of a novel 5-HT4 receptor agonist, DSP-6952
    Tsubouchi, Tadashi
    Kunimatsu, Takeshi
    Tsujimoto, Shinji
    Kiyoshi, Akihiko
    Katsura, Yasunori
    Oku, Seiko
    Chihara, Kazuhiro
    Mine, Yukiko
    Yamada, Toru
    Shimizu, Isao
    Bando, Kiyoko
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 826 : 96 - 105
  • [30] A Multivalent Approach to the Design and Discovery of Orally Efficacious 5-HT4 Receptor Agonists
    McKinnell, R. Murray
    Armstrong, Scott R.
    Beattie, David T.
    Choi, Seok-Ki
    Fatheree, Paul R.
    Gendron, Roland A. L.
    Goldblum, Adam
    Humphrey, Patrick P.
    Long, Daniel D.
    Marquess, Daniel G.
    Shaw, J. P.
    Smith, Jacqueline A. M.
    Turner, S. Derek
    Vickery, Ross G.
    JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (17) : 5330 - 5343